Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
Verve Therapeutics saw its stock surge by more than 26% when markets opened today (14 April) after the company announced…
-
FDA to phase out animal testing with AI and lab-based models
The US Food and Drug Administration (FDA) has announced plans to begin replacing animal testing in drug development with “more…
-
EU president to meet pharma leaders as tariff threat looms
European Commission (EC) President Ursula von der Leyen is set to hold talks with senior pharmaceutical executives today (8 April),…
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
-
HHS announces major workforce cuts and reorganisation
The US Department of Health and Human Services (HHS) will cut 10,000 full-time employees and restructure its divisions as part…
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate…
-
Investigating key strategies for optimising clinical trial supply chains in 2025
As the clinical trial landscape evolves with a growing demand for efficiency, flexibility, and innovation in 2025, experts will gather…
-
The trillion-dollar opportunity in women’s health
Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP)…
-
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now halted its own…
